Stephen Morairty, Ph.D., is a neurophysiologist who leads the preclinical in vivo pharmacology group, which investigates the actions of central nervous system (CNS)-targeted compounds.
Morairty is an expert at interpreting measures of sleep and wakefulness, as well as in performing quantitative analysis of the electroencephalogram (qEEG). In addition to pioneering work correlating CNS drug efficacy profiles with EEG spectral profiles, he has a strong interest in the use of the EEG as a translational biomarker for measuring the presence and progression of neurodegenerative disease.
He has worked with more than 15 pharmaceutical companies and private foundations, and has performed more than 100 pharmaco-EEG studies. Recently, he has combined EEG with other behavioral assays such as the Morris Water Maze and the rodent psychomotor vigilance test. This work investigates the changes in qEEG profiles following administration of compounds that change cognitive performance.
Morairty received his Ph.D. in neuroscience from UCLA and completed his post-doctoral fellowship at Harvard Medical School's Department of Psychiatry.